In addition to the exploratory preclinicals on oth

In addition to the exploratory preclinicals on other oncology indications (TNBC), papers, and mouse studies, we also have Two trials with people, mssCRC and Alzheimer's Plus an inflammation trial that will get under way soon (or maybe it has already).

Someone remind me of when the inflammation trial will commence or when it already commenced, and when it is likely to show results. The point is, in just a year or so, Dr J and team have done an outstanding job of moving this company forward. My bet is on them.

All of these trials involving people will provide data, and this will enable the share price to move higher and blow the short sellers away. Those who are smart will buy-to-cover soon. Those who don't will pay the price eventually.

In the meantime, as a shareholder of 4 years (adding all the time, as money permits) I'm going to sit back, relax, and wait for the data to provide a licensing opportunity or partnership, or opportunity (in the case of Alzheimers) to provide funding alone.

Dr J said they have the funding they need for now, and so long as I don't sell now, then I can partake of the rewards when the data comes in. Staying Long, Adding, and Ignoring the background noise.

I won't make the same mistake I made with Apple. And I'm not looking for an Apple here, just a company that will truly help people and reward us handsomely in the meantime

Go LL
Ramjet